TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2212369
Drug: dual pathway
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dual pathway sequential pulsing
Study: 25733317
Drug: ivabradine (10-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine (10-15 mg/day for 6 months)
Study: 21700416
Drug: Control period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control period (ordinary treatment)
Study: 19565732
Drug: Acupoint application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint application of Chinese medicine at Dazhui (GV 14), Feishu (BL 13), Gaohuang (BL 43), Danzhong (CV 17), Qihai (CV 6)
Study: 11373411
Drug: Lenercept (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenercept (0.125 mg/kg intravenous)
Study: 9266384
Drug: New amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: New amino acid formulation and treatment products
Study: 24737678
Drug: Thioguanine treatment
Normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thioguanine treatment arm (CCG‐1952 clinical trial)
Study: 24737678
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MTHFR and TPMT variant genotypes
Study: 22420475
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 mL)
Study: 22420475
Drug: Morphine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (1 mL)
Study: 16218969
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (1 mL)
Study: 11429337
Drug: Fenoldopam infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam infusion at 1.3 +/- 0.4 microg.kg(-1).min(-1)
Study: 11429337
Drug: Concurrent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent infusion of phenylephrine
Study: 9531030
Drug: Desirudin (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desirudin (10, 15 or 20 mg b.i.d.)
Study: 2737311
Drug: Intramuscular analgesics
Normalized name: ANALGESIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular analgesics given at fixed hours (methadone 10 mg i.m. every 12 h for days 1-3; sodium diclofenac 75 mg i.m. every 12 h for days 4-7)
Study: 2737311
Drug: Intramuscular analgesics
Normalized name: ANALGESIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular analgesics given at fixed hours
Study: 2737311
Drug: Drugs 'on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs 'on demand' or not treated at all
Study: 342618
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza A/New Jersey/76 virus vaccines (200, 400, or 800 chick cell-agglutinating units)
Study: 342618
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza A/New Jersey/76 virus vaccines (all dosages)
Study: 342618
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza A/New Jersey/76 virus vaccines
Study: 30472196
Drug: NT-proBNP levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP levels < 45 ng/L
Study: 25735317
Drug: Bevacizumab (B)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (B) added to standard chemotherapy (CT)
Study: 25735317
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (CT) only
Study: 24968500
Drug: Injection lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection lignocaine (preservative free) 1.5 mg/kg i.v.
Study: 24968500
Drug: Oral pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral pregabalin 150 mg capsule
Study: 19233341
Drug: Any aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Any aspirin use (self-selected)
Study: 8080611
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 400 micrograms BD for eight weeks
Study: 8080611
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for four weeks
Study: 2947537
Drug: Cefoperazone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone 0.5 g
Study: 2947537
Drug: Cefoperazone 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone 1.0 g
Study: 2947537
Drug: Spectinomycin 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spectinomycin 2.0 g
Study: 20299470
Drug: Rosiglitazone (peroxisome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (peroxisome proliferator-activated receptor agonist)
Study: 10640259
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg zolmitriptan
Study: 18541561
Drug: Sesame oil
Normalized name: Sesame Oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sesame oil muffin consumption (sesamin, 94 mg; sesamolin, 42 mg)
Study: 15325678
Drug: Diet containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet containing 10.4 g/d of fiber
Study: 15325678
Drug: Diet containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet containing 30.5 g/d of fiber
Study: 9287967
Drug: Octreotide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (200 micrograms daily)
Study: 8394061
Drug: Granisetron (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (2 mg once a day for 6 consecutive days)
Study: 8394061
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antiemetic treatment)
Study: 2872260
Drug: Treatment phase
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment phase completion
Study: 29238506
Drug: Gabapentin, titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin, titrated from 300 mg/day to a maximum of 900 mg/day
Study: 29238506
Drug: Topiramate, titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate, titrated from 50 mg/day to a maximum of 100 mg/day
Study: 25494032
Drug: Sodium phosphate
Normalized name: Sodium Phosphate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium phosphate supplementation (50 mg · kg·fat‐free‐mass⁻¹ · day⁻¹; n = 7)
Study: 17207671
Drug: Regular physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular physical therapy
Study: 21692299
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (compound general anesthesia with meridian points)
Study: 21692299
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (compound general anesthesia with placebo points)
Study: 10684705
Drug: Paclitaxel-containing chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel-containing chemotherapy
Study: 8360132
Drug: Loracarbef 400
Normalized name: loracarbef 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loracarbef 400 mg bd
Study: 8360132
Drug: Doxycycline 200
Normalized name: doxycycline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 200 mg for the first dose followed by 100 mg od
Study: 3739357
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg theophyllinethylendiamine (Euphyllin)
Study: 3739357
Drug: Combined medication
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined medication consisting of 25 mg theophyllin, 85 mg etophyllin, 30 mg papaverine and 0.1 mg atropine methylnitrate (Perphyllon)
Study: 24702786
Drug: Comprehensive mental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive mental intervention (support, counselling, music, massage plus conventional therapy)
Study: 24702786
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (three‐cavity gastric tube, fasting, parenteral/enteral nutrition, routine care, health guidance)
Study: 17658101
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral administration of a placebo medication and preincision local infiltration of 40 mL of 0.5 per cent bupivicaine at trocar sites
Study: 17658101
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral administration of 50 mg of rofecoxib
Study: 17658101
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral administration of 50 mg of rofecoxib and preincision local infiltration of 40 mL of 0.5 per cent bupivicaine
Study: 17658101
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral administration of a placebo medication
Study: 11470697
Drug: timolol gel
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: timolol gel 0.5%
Study: 10085699
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of nephropathy, duration of renal treatment, duration of dialysis treatment
Study: 24433231
Drug: I Can
Normalized name: DIPHENHYDRAMINE HYDROCHLORIDE 25 mg ORAL TABLET [Help I cant Sleep]
Approvals — FDA: no, EMA: no, PMDA: no
Description: I Can Cope (4 sessions: learning about cancer; understanding cancer treatments; relieving cancer pain; keeping well in mind and body)
Study: 24433231
Drug: Wellness intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wellness intervention (4 sessions: humor, meditation, relaxation, and music therapy)
Study: 23185761
Drug: Youdujing (YDJ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Youdujing (YDJ) external lotion and YDJ cream
Study: 23185761
Drug: Youdujing (YDJ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Youdujing (YDJ) treatment
Study: 20473630
Drug: Ribonuclease-enriched lactoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribonuclease-enriched lactoferrin (R-ELF) supplementation (2 × 125 mg/day)
Study: 20473630
Drug: Placebo (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (calcium supplement only)
Study: 11753129
Drug: Bladder infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bladder infusion prior to catheter removal
Study: 11753129
Drug: Ethanol‐glycine in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol‐glycine in assessment of the absorption of irrigation fluid
Study: 8839904
Drug: Tecogalan sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tecogalan sodium (dosage levels: 125, 185, 240, 300, 390, 445, and 500 mg/m2) administered via single i.v. infusion every three weeks for 1 to 24 hours.
Study: 8839904
Drug: Tecogalan sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tecogalan sodium at the recommended phase II dose of 390 mg/m2 over 24 hours.
Study: 6386932
Drug: Oral amrinone
Normalized name: AMRINONE
DrugBank: Amrinone (DB01427)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral amrinone (113 +/- 33 mg three times daily)
Study: 6386932
Drug: Oral amrinone
Normalized name: AMRINONE
DrugBank: Amrinone (DB01427)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral amrinone
Study: 6386932
Drug: Oral amrinone
Normalized name: AMRINONE
DrugBank: Amrinone (DB01427)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral amrinone and Placebo
Study: 31279306
Drug: Chemotherapy (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (in PENELOPE validation cohort)
Study: 31279306
Drug: Bevacizumab-chemotherapy (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab-chemotherapy (in AURELIA validation cohort)
Study: 16306520
Drug: Acetylcysteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcysteine (600 mg three times daily)
Study: 8331205
Drug: Adinazolam mesylate
Normalized name: mesylate
DrugBank: Adinazolam (DB00546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adinazolam mesylate immediate-release (CT) tablets (2 x 20 mg)
Study: 8331205
Drug: Adinazolam sustained-release
Normalized name: adinazolam
DrugBank: Adinazolam (DB00546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adinazolam sustained-release (SR) tablets (2 x 30 mg)
Study: 31544802
Drug: Nutritional rehabilitation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional rehabilitation (NR) for 9±2 months with nutritional counselling and oral nutritional supplementation (n = 51)
Study: 28363880
Drug: Web-based CPD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based CPD program on providing oral hygiene care to stroke patients using TPB
Study: 28363880
Drug: Web-based CPD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based CPD program not specific to oral hygiene
Study: 20977368
Drug: Linezolid 600
Normalized name: linezolid 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid 600 mg
Study: 21709083
Drug: Linezolid 1200
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid 1200 mg
Study: 21709083
Drug: Linezolid 1200
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid 1200 mg vs 600 mg
Study: 28342632
Drug: Low-dose ticagrelor
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ticagrelor (90mg loading dose, then 90mg daily)
Study: 28342632
Drug: Standard-dose ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose ticagrelor (180mg loading dose, then 90mg twice daily)
Study: 28342632
Drug: Clopidogrel (300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300mg loading dose, then 75mg daily)
Study: 25620535
Drug: Etifoxine 150
Normalized name: etifoxine
DrugBank: Etifoxine (DB08986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etifoxine 150 mg/day for 28 days
Study: 25620535
Drug: Alprazolam 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 1.5 mg/day for 28 days
Study: 19067864
Drug: Corticosteroids (from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (from twice daily to one application every other day) combined with the studied cream (twice daily)
Study: 19067864
Drug: Studied cream
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Studied cream (twice daily)
Study: 19067864
Drug: Corticosteroids alone
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids alone (once or twice daily)
Study: 14681620
Drug: External jugular
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External jugular vein (EJV) patch
Study: 14681620
Drug: Polytetrafluoroethylene (PTFE)
Normalized name: polytetrafluoroethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polytetrafluoroethylene (PTFE) patch
Study: 9241289
Drug: Prediction model
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prediction model with additional variable of need for labor augmentation.
Study: 3584272
Drug: Oros drug
Normalized name: Oro Clense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oros drug delivery system (10/170 oxprenolol)
Study: 3584272
Drug: Slow Trasicor
Normalized name: Slow Trasicor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow Trasicor 160 mg orally
Study: 3584272
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of pre‐equilibrated Oros systems
Study: 23591255
Drug: Continuous-combined estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous-combined estradiol 1 mg/drospirenone 2 mg (E2D)
Study: 21990176
Drug: Baclofen 10
Normalized name: baclofen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen 10 mg, 3 times per day, orally
Study: 18496952
Drug: Emergency bypass
Normalized name: factor VIII inhibitor bypassing activity
DrugBank: Anti-inhibitor coagulant complex (DB13151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency bypass for therapy refractory vasospasm (group II)
Study: 12652173
Drug: Intravenous amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone loading for 24 hours
Study: 10912543
Drug: Deflazacort (0.30+/‐0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deflazacort (0.30+/‐0.03 mg/kg per day)
Study: 1643923
Drug: Inhaled furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled furosemide (20 mg)
Study: 6228459
Drug: 3 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 micrograms heat-inactivated HBsAg vaccine
Study: 6228459
Drug: 27 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 27 micrograms heat-inactivated HBsAg vaccine
Study: 31376515
Drug: Artemisia afra
Normalized name: Artemisia vulgaris top oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisia afra extracts and compounds
Study: 26332605
Drug: VRC01 intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC01 intravenous (i.v.) infusion at 20 mg/kg
Study: 26332605
Drug: VRC01 intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC01 intravenous (i.v.) infusion at 40 mg/kg
Study: 26332605
Drug: VRC01 subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC01 subcutaneous (s.c.) delivery at 5 mg/kg
Study: 26332605
Drug: Placebo s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo s.c. given twice, 28 days apart
Study: 26332605
Drug: VRC01 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC01 (all doses)
Study: 26332605
Drug: VRC01 (5-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC01 (5-40 mg/kg i.v. range)
Study: 19127261
Drug: WBRT+topotecan (RCT;
Approvals — FDA: no, EMA: no, PMDA: no
Description: WBRT+topotecan (RCT; 0.4 mg m(‐2) day(‐1) x 20)
Study: 18379495
Drug: Antianginal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antianginal and metabolic therapy
Study: 15475832
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g oleic capsaicin-containing patches
Study: 9769871
Drug: 2 nucleoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 nucleoside analogues and a protease inhibitor
Study: 2390434
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg mefloquine base weekly
Study: 2390434
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg mefloquine base weekly
Study: 27258249
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg FeLf (iron-lactoferrin complex) per day
Study: 23791561
Drug: Neck manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neck manual therapy
Study: 23791561
Drug: Pragmatic, evidence-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pragmatic, evidence-based treatment to the shoulder (control group)
Study: 22995971
Drug: Warfarin anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin anticoagulation with INR of 2 to 3
Study: 16047062
Drug: Screening program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening program including free and total prostate specific antigen (PSA) and digital rectal examination (DRE)
Study: 7874873
Drug: Low-dose warfarin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose warfarin with responsive thromboplastin
Study: 7874873
Drug: High-dose warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose warfarin with high international sensitivity index thromboplastin
Study: 2965227
Drug: Diuretics and
Normalized name: Low-ceiling diuretics and potassium-sparing agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics and vasodilating agents (added where blood pressure was insufficiently controlled)
Study: 2965227
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (beta-blockers and methyldopa)
Study: 31955619
Drug: TNF‐α inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF‐α inhibitor (Group A)
Study: 31955619
Drug: Steroid (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid (Group B)
Study: 30343318
Drug: 2-L/kg/min high-flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-L/kg/min high-flow nasal cannula (HFNC)
Study: 30343318
Drug: 3-L/kg/min high-flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-L/kg/min high-flow nasal cannula (HFNC)
Study: 21966753
Drug: Progesterone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (100 mg/day IM)
Study: 21966753
Drug: Estradiol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol (2 mg of estradiol valerianate) plus progesterone (100 mg/day IM)
Study: 12161047
Drug: Menorest 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menorest 50 microg/24 h (estradiol 4.3 mg) and Gestapuran 2.5 mg (medroxyprogesteron) daily
Study: 10583115
Drug: 10 p.p.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 p.p.m. nickel concentration in water for 10 min daily for the first week, followed by 100 p.p.m. nickel concentration for the second week
Study: 31536101
Drug: Linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 5 mg once daily (n=3023)
Study: 31536101
Drug: Glimepiride 1
Normalized name: glimepiride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 1 to 4 mg once daily (n=3010)
Study: 24524204
Drug: Daily Sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Sedation Interruption (DSI) in combination with protocolized sedation
Study: 22871933
Drug: Zilpaterol HCl
Normalized name: zilpaterol
DrugBank: Zilpaterol (DB11479)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zilpaterol HCl (8.33 mg/kg DM)
Study: 22871933
Drug: Zilpaterol HCl
Normalized name: zilpaterol
DrugBank: Zilpaterol (DB11479)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zilpaterol HCl (8.33 mg/kg DM) with 148 DOF
Study: 20298254
Drug: 1,064‐nm Q‐switched
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,064‐nm Q‐switched neodymium-doped yttrium aluminum garnet (QS‐Nd:YAG) laser treatment
Study: 20298254
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment (2% hydroquinone)